HTB

2008

Volume 9 Number 11/12 November/December 2008

i-BASE APPEAL

48th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25-28 October 2008, Washington DC

Antiretroviral Pregnancy Registry finds no increase in congenital anomalies with exposure to tenofovir

No association between maternal antiretrovirals in pregnancy and congenital anomalies

Pharmacokinetics of saquinavir/ritonavir in pregnancy

Course of labour in pregnant HIV-positive women with no contraindication for vaginal delivery

Four weeks of antiretroviral prophylaxis is sufficient for HIV-exposed infants

HAART suppresses genital tract HIV shedding in HIV/HSV co-infected women

Efavirenz significantly reduces levels of some oral contraceptives

Lack of efficacy of isoniazid (INH) prophylaxis and PK evaluation in South African infants

48-week data for darunavir/ritonavir (DRV/r) in treatment-experienced children and adolescents

Greater lipodystrophy risk in older US children with low viral load

Studies of pipeline drugs: RDEA806, PRO140, bevirimat, elvucitabine

Maraviroc trial results reanalysed using more sensitive CCR5 tropism test

Other antiretroviral studies at ICAAC

High rate of rash in HIV negative volunteers combining raltegravir and darunavir

Bone loss in SMART study

Parathyroid hormone and vitamin D levels in patients using tenofovir

Haemoglobin A1c (HbA1c) may underestimate glycaemia in patients with diabetes on HIV therapy

Statin use in HIV-positive patients

HIV reinfection reported in 10% of couples in Zambian study

Drug interaction studies with approved drugs

FDA approval of generic ARVs

Non alcoholic fatty liver disease (NAFLD) is common among HIV-positive patients

FDA approves new paediatric AZT dosing

US revisions to darunavir label include once-daily indication for naive patients

Baseline renal insufficiency and mortality risk in HIV-positive adults in Zambia

Inflammatory and coagulation biomarkers linked to mortality in large treatment interruption trial

Single high dose fluconazole for oropharyngeal candidiasis

IAS (USA) resistance guidelines

BHIVA guidelines for immunisation of HIV-infected adults (2008)

2008 European Guidelines (EACS) online

US guidelines updated – November 2008

OCTANE Trial DSMB finds ritonavir-boosted lopinavir superior to nevirapine in HIV-positive women previously exposed to single dose nevirapine

Antiretroviral therapy in pregnant women and pregnancy outcomes in Abidjan, Cote D’Ivoire

Key papers on methadone and ritonavir

Antiretroviral therapy in HIV-positive children in Southern Africa

Control of a superinfecting virus in an elite controller

Second-oldest HIV-1 sequence identified

Why do we not yet have an HIV vaccine?

Nobel Prize for medicine awarded to French discoverers of HIV

Chinese AIDS activist wins human rights prize

Abstracts from the 9th International Congress on Drug Therapy in HIV Infection

Abstracts from AIDS Vaccine 2008

Abstracts from BHIVA Autumn Conference, 9-10 October 2008

Volume 9 Number 11/12 November/December 2008 PDF

Volume 9 Number 9/10 Sep/Oct 2008

17th International AIDS Conference, 3-8 August 2008, Mexico City

Abacavir and heart disease: SMART study supports an abacavir-associated increased risk of cardiovascular disease

HAART use in pregnancy and preterm delivery and low birth weight

Reasons for mother to child transmission in England

New paediatric formulations of ARVs

3rd International Transmission Workshop, 1-2 August 2008, Mexico City

Intermittent tenofovir/FTC PrEP offers monkeys some protection

Tenofovir/FTC gel protects female monkeys from SHIV

Recently infected HIV-positive Quebec residents cause more than half of new cases

Common estimate of heterosexual HIV transmission risk sometimes far too low

US cancel phase 3 HIV vaccine trial

Detained Chinese AIDS activist quietly sentenced during Olympics

Free The Iranian HIV/AIDS Doctors!

Brazil rejects Gilead patent on tenofovir

PEPFAR bill may lift US HIV travel and residency ban

Opportunity for doctor to work in Thailand

EMEA state that animal studies support no increased risk of malignancy from contamination of nelfinavir (Viracept) with ethyl mesilate (EMS)

Post navigation